Building on this ADME–PK foundation for small molecules and peptides, Viva applies modality-specific strategies to antibody programs, where FcRn biology becomes a central determinant of pharmacokinetic behavior. A central technical highlight was Viva Biotech's engineered hFcRn/B2M–MDCK Transwell system for antibody transcytosis, developed to generate a cell-based readout of FcRn-mediated transport and to enable time- and dose-dependent transcytosis measurements. Positioned as a cost- and time-efficient appr ...